Sapient Capital LLC Has $11.59 Million Stock Holdings in Pfizer Inc. $PFE

Sapient Capital LLC reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 4.3% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 485,216 shares of the biopharmaceutical company’s stock after selling 21,658 shares during the quarter. Sapient Capital LLC’s holdings in Pfizer were worth $11,586,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. GKV Capital Management Co. Inc. bought a new stake in Pfizer during the 1st quarter worth approximately $27,000. Curio Wealth LLC grew its stake in shares of Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,098 shares during the last quarter. Bayforest Capital Ltd acquired a new stake in Pfizer in the first quarter valued at $28,000. Harbor Asset Planning Inc. bought a new position in Pfizer during the 2nd quarter worth $29,000. Finally, Howard Hughes Medical Institute bought a new position in Pfizer during the 2nd quarter worth $30,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.3%

Shares of PFE stock opened at $25.10 on Friday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.69. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. The stock has a 50 day simple moving average of $25.16 and a two-hundred day simple moving average of $24.89. The company has a market cap of $142.68 billion, a P/E ratio of 14.59 and a beta of 0.46.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.79 by $0.08. The company had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.9%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s payout ratio is 100.00%.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of analyst reports. BMO Capital Markets reiterated an “outperform” rating on shares of Pfizer in a research report on Wednesday, December 10th. Citigroup initiated coverage on Pfizer in a report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 target price on the stock. Bank of America decreased their target price on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research report on Monday, December 15th. Scotiabank initiated coverage on shares of Pfizer in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $28.06.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.